Go2 Foundation for Lung Cancer-fka Lca- on Behalf of Deadliest Cancers Coalition
lung cancer advocacy
Based in DC
🤖
AI Overview
With $225K in lobbying spend across 33 quarterly filings, Go2 Foundation for Lung Cancer-fka Lca- on Behalf of Deadliest Cancers Coalition is an active lobbying client. Their lobbying covers 4 issue areas. Active from 2018 to 2025.
$225K
Total Spend
8
Years Active
1
Firms Hired
1
Lobbyists Deployed
4
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2018 | $0 |
| 2019 | $50K |
| 2020 | $60K |
| 2021 | $50K |
| 2022 | $30K |
| 2023 | $20K |
| 2024 | $15K |
| 2025 | $0 |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Budget/Appropriations, Medicare/Medicaid, MED
- •Advocating on behalf of the deadliest cancers, which are defined as those with a five-year survival rate below 50 percent.
- •Funding for NCI in the FY19 Labor, Health & Human Services, and Education Appropriations bills
- •Report language on deadliest cancers in the FY19 Labor, Health & Human Services, and Education Appropriat
- •Medicare Part B proposals outlined in President Trumps Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs and corresponding Request for Information (RFI)
Related Analysis
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
The 22,000% ROI
When lobbying spending yields outsized returns.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.